CoChat

An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity

Open access
Weisser, Nina E., Sanches, Mario, Escobar-Cabrera, Eric, O’Toole, Jason, Whalen, Elizabeth, Chan, Peter W. Y., Wickman, Grant, Abraham, Libin, Choi, Kate, Harbourne, Bryant, Samiotakis, Antonios, Rojas, Andrea Hernández, Volkers, Gesa, Wong, Jodi, Atkinson, Claire E., Baardsnes, Jason, Worrall, Liam J., Browman, Duncan, Smith, Emma E., Baichoo, Priya, Cheng, Chi Wing, Guedia, Joy, Kang, Sohyeong, Mukhopadhyay, Abhishek, Newhook, Lisa, Ohrn, Anders, Raghunatha, Prajwal, Zago-Schmitt, Matteo, Schrag, Joseph D., Smith, Joel, Zwierzchowski, Patricia, Scurll, Joshua M., Fung, Vincent, Black, Sonia, Strynadka, Natalie C. J., Gold, Michael R., Presta, Leonard G., Ng, Gordon, Dixit, Surjit · 2023 · Nature Communications
Cited by 185

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase that plays an oncogenic role in breast, gastric and other solid tumors. However, anti-HER2 therapies are only currently approved for the treatment of breast and gastric/gastric esophageal junction cancers and treatment resistance remains a problem. Here, we engineer an anti-HER2 IgG1 bispecific, biparatopic antibody (Ab), zanidatamab, with unique and enhanced functionalities compared to both trastuzumab and the combination of trastuzumab plus pertuzumab (tras + pert). Zanidatamab binds adjacent HER2 molecules in trans and initiates distinct HER2 reorganization, as shown by polarized cell surface HER2 caps and large HER2 clusters, not observed with trastuzumab or tras + pert. Moreover, zanidatamab, but not trastuzumab nor tras + pert, elicit potent complement-dependent cytotoxicity (CDC) against high HER2-expressing tumor cells in vitro. Zanidatamab also mediates HER2 internalization and downregulation, inhibition of both cell signaling and tumor growth, antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), and also shows superior in vivo antitumor activity compared to tras + pert in a HER2-expressing xenograft model. Collectively, we show that zanidatamab has multiple and distinct mechanisms of action derived from the structural effects of biparatopic HER2 engagement.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-37029-3

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 185

Metadata

Authors
Weisser, N. E., Sanches, M., Escobar-Cabrera, E., O’Toole, J., Whalen, E., Chan, P. W. Y., Wickman, G., Abraham, L., Choi, K., Harbourne, B., Samiotakis, A., Rojas, A. H., Volkers, G., Wong, J., Atkinson, C. E., Baardsnes, J., Worrall, L. J., Browman, D., Smith, E. E., Baichoo, P., Cheng, C. W., Guedia, J., Kang, S., Mukhopadhyay, A., Newhook, L., Ohrn, A., Raghunatha, P., Zago-Schmitt, M., Schrag, J. D., Smith, J., Zwierzchowski, P., Scurll, J. M., Fung, V., Black, S., Strynadka, N. C. J., Gold, M. R., Presta, L. G., Ng, G., & Dixit, S.
Venue
Nature Communications
Published
2023-03-13
Volume
14
Issue
1
Pages
1394-1394
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4324129029
Cited by
185
References
3
FWCI
19.15
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. https://app.cochat.ai/papers/10.1038/s41467-023-37029-3
The paper
Weisser, N. E., Sanches, M., Escobar-Cabrera, E., O’Toole, J., Whalen, E., Chan, P. W. Y., Wickman, G., Abraham, L., Choi, K., Harbourne, B., Samiotakis, A., Rojas, A. H., Volkers, G., Wong, J., Atkinson, C. E., Baardsnes, J., Worrall, L. J., Browman, D., Smith, E. E., . . . Dixit, S. (2023). An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nature Communications. https://doi.org/10.1038/s41467-023-37029-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.